Vilanterol/fluticasone furoate is a combination medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It combines a long-acting beta2-adrenergic agonist (LABA) with an inhaled corticosteroid (ICS). Vilanterol relaxes the muscles in the airways, while fluticasone furoate reduces inflammation.
When does the patent for vilanterol/fluticasone expire?
The patent expiration for vilanterol/fluticasone varies by specific formulation and market. For instance, Breo Ellipta, which contains vilanterol and fluticasone furoate, has faced patent challenges and expirations in different regions. Information on patent status for specific drug formulations can be found on DrugPatentWatch.com [1].
What other medications are similar to vilanterol/fluticasone?
Other medications for asthma and COPD that combine an ICS with a LABA include:
* Budesonide/formoterol (Symbicort)
* Fluticasone propionate/salmeterol (Advair Diskus, Advair HFA)
* Mometasone furoate/formoterol (Dulera)
* Budesonide/arformoterol (Symbicort) [2]
How do vilanterol/fluticasone treatments work for COPD?
Vilanterol, the LABA component, works by relaxing the smooth muscles in the airways, which helps to open them up and improve airflow in individuals with COPD. Fluticasone furoate, the ICS component, works by reducing the inflammation present in the airways, a key characteristic of COPD that contributes to breathlessness and exacerbations [3].
What are the risks associated with vilanterol/fluticasone?
Potential risks and side effects of vilanterol/fluticasone include an increased risk of pneumonia in COPD patients, paradoxical bronchospasm, and effects on the immune system due to the corticosteroid component. Long-term use of LABAs without an ICS has also been associated with an increased risk of severe asthma exacerbations and death [4].
Can I use vilanterol/fluticasone for asthma?
Yes, vilanterol/fluticasone medications are indicated for the maintenance treatment of asthma in patients aged 18 years and older. They are not intended for the relief of acute bronchospasm [5].
What is the difference between vilanterol and fluticasone?
Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that acts as a bronchodilator, meaning it relaxes the muscles in the airways to make breathing easier. Fluticasone furoate is an inhaled corticosteroid (ICS) that works to reduce inflammation in the airways. They are often used together to manage chronic respiratory conditions [1, 3].
What is the mechanism of action for vilanterol and fluticasone?
Vilanterol stimulates beta2-adrenergic receptors in the lungs, leading to smooth muscle relaxation and bronchodilation. Fluticasone furoate is a synthetic corticosteroid that, when inhaled, suppresses the release of inflammatory mediators, reduces edema, and decreases the activity of inflammatory cells, thereby decreasing airway inflammation [3].
Who manufactures vilanterol/fluticasone medications?
Vilanterol/fluticasone furoate is developed and manufactured by GlaxoSmithKline (GSK).
What are the approved uses for vilanterol/fluticasone?
Vilanterol/fluticasone furoate is approved for two main uses: the maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema, and as a maintenance treatment of asthma in patients 18 years of age and older [5].
Are there any generic versions of vilanterol/fluticasone available?
The availability of generic versions of vilanterol/fluticasone can vary by region and depend on patent expirations and regulatory approvals. DrugPatentWatch.com tracks patent information that influences generic availability [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658377/
[3] https://www.fda.gov/media/89108/download
[4] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients/ asthma-and-long-acting-beta-agonists-laba-questions-and-answers
[5] https://www.gsksource.com/us/en/our-products/respiratory/breo-ellipta